X

Meibomian Gland Dysfunction Treatment Market, By Drug Type (Cyclosporine, Omega-3 Supplements, Antib

Published Date: | Report Code : HC2169828

X

Meibomian Gland Dysfunction Treatment Market, By Drug Type (Cyclosporine, Omega-3 Supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03, HY02 – Minocycline), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Region (North America, Europe, Asia Pacific, Middle East and Africa, South America) — Market Size and Forecasting to 2030

COVID-19 Impact : Our team has been closely monitoring the current developments to identify the potential impact of COVID-19 on stakeholders and business processes across the value chain of industries. A special section about COVID-19 will be covered with the report to help companies in defining sustainable strategies.

Domain : Healthcare

Report Code : HC2169828

Status : Published

The Global Meibomian Gland Dysfunction Treatment Market has been estimated to reach USD 158.6 billion in 2021 and is estimated to grow at a CAGR of 9.2% during the forecast period. Meibomian glands play a significant role in the production of tears, and dysfunction of these glands leads to evaporative dry eye disease. Meibography is a technique designed mainly for the in-vivo visualization of these glands. Meibography techniques are mainly classified into non-contact and contact techniques. The meibomian gland dysfunction is classified into four types, where grade 0 is the best level depicting appropriate functioning, and grade 4 states the highest level of evaporative eye dryness, which considerably impacts the quality of the patient’s life.

Increasing pollution, changing environmental situations, and use of electronic devices such as mobiles and laptops are the major factors leading to meibomian gland dysfunction and dry eye syndrome. The developing companies operating in the market are majorly focusing on addressing the unmet medical requirements to detect the major underlying causes of dry eye disease to offer the optimal solution to the meibomian gland dysfunction treatment market.

Increasing prevalence of dry eye disease, awareness among ophthalmologists, and technological innovations in imaging analysis are expected to drive the market growth during the forecast period. In addition, optometrists for the appropriate detection of meibomian gland dysfunction are the factors that are expected to propel the market during the forecast period. On the other hand, accessibility of other substitute tests to identify the dry eye syndrome is estimated to acts as a restrain for the market during the forecast period.

The QMI team is closely observing the impact of COVID-19 on the meibomian gland dysfunction treatment market. Rise in the use of visual display terminals during the lockdown and restrictions of constant visits to ophthalmologists resulted in increased number of dry eye patients. Increased face mask-related dry eye conditions and increased screen time are anticipated to fuel the development rate in the near future. This is expected to boost market growth during the COVID-19 outbreak.

TABLE 1: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET OVERALL SNAPSHOT

TABLE 1: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET OVERALL SNAPSHOT

Market Segmentation

The meibomian gland dysfunction treatment market is segmented based on drug type, route of administration, distribution channel, and region.

FIGURE 1: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET SEGMENTATION

FIGURE 1: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET SEGMENTATION

Global Meibomian Gland Dysfunction Treatment Market, by Drug Type

Based on drug type, the meibomian gland dysfunction treatment market is segmented into cyclosporine, omega-3 supplements, antibacterial eye drops, steroids, AZR MD 001, TP 03, NOV03 (novatears), and HY02 – minocycline.

The antibacterial eye drops segment holds the largest market share in 2021, and is expected to remain the largest market during the forecast period. Antibacterial eye drops relief the symptoms like dry eyes and also relief meibomian gland dysfunction symptoms. This is expected to drive the segment growth.

Global Meibomian Gland Dysfunction Treatment Market, by Route of Administration

Based on route of administration, the meibomian gland dysfunction treatment market is segmented into oral and topical.

The topical segment holds the largest market share in 2021, and is expected to remain largest market during the forecast period. Topical route of administration has been shown to be a potentially effective and well accepted treatment for meibomian gland dysfunction. Additionally, topical therapy could lead to clinical relief or control of signs and symptoms of meibomian gland dysfunction and development in lipid behaviors of meibomian gland secretion. These factors are expected to drive segment growth during the forecast period.

Global Meibomian Gland Dysfunction Treatment Market, by Distribution Channel

Based on distribution channel, the meibomian gland dysfunction treatment market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment holds the largest market share in 2021, and is expected to remain the largest market during the forecast period. Increased interaction with prescribers and other health professionals, and greater input in prescribing decisions about drugs and administration are expected to drive the segment growth.

In addition, the larger team of pharmacists operational in the same institution, and improved access to medical records of patients are also expected to contribute to segment growth during the forecast period.

Global Meibomian Gland Dysfunction Treatment Market, by Region

Based on region, the meibomian gland dysfunction treatment market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and South America. North America holds the largest market share in 2021, and is expected to remain largest market during the forecast period. The regional market growth can be attributed to well-defined reimbursement rules from private and public health insurance companies that offer patients easy access to treatment and diagnosis.

Asia Pacific is expected to be the fastest growing region during the forecast period. The regional market growth can be on account of a surge in patient population and an increase in acceptance of treatment in the region.

TABLE 2: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET OVERVIEW

TABLE 2: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET OVERVIEW

FIGURE 2: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET (USD BILLION), 2021-2030

 FIGURE 2: GLOBAL MEIBOMIAN GLAND DYSFUNCTION TREATMENT MARKET (USD BILLION), 2021-2030

Recent Developments in the Meibomian Gland Dysfunction Treatment Market

  • June 2019- AbbVie declared a definitive transaction contract with Allergen, under which AbbVie acquired Allergan Plc., (Allergan), a global pharmaceutical leader focused on developing, manufacturing, and commercializing branded device, pharmaceutical, biologic, surgical and regenerative medicine products for patients worldwide. The acquisition will support Abbvie to expand its product portfolio.
  • August 2018- Sun Pharma received authorization for Cequa (cyclosporine ophthalmic solution) 0.09% from the U.S. FDA. The drug is specified for increasing tear production in patients with dry eye disease. Cequa is the only permitted cyclosporine product that incorporates nanomicellar technology and permits better penetration of active molecule into ocular tissues.

By Drug Type

  • Cyclosporine
  • Antibacterial Eye Drops
  • Omega-3 supplements
  • Steroids
  • HY02 – Minocycline
  • AZR MD 001
  • TP 03
  • NOV03 (Novatears)

By Route of Administration

  • Topical
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

 North America Meibomian Gland Dysfunction Treatment Market

  • North America, by Country
    • U.S.
    • Canada
    • Mexico
  • North America, by Drug Type
  • North America, by Route of Administration
  • North America, by Distribution Channel

Europe Meibomian Gland Dysfunction Treatment Market

  • Europe, by Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe 
  • Europe, by Drug Type
  • Europe, by Route of Administration
  • Europe, by Distribution Channel

Asia Pacific Meibomian Gland Dysfunction Treatment Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia Pacific 
  • Asia Pacific by Drug Type
  • Asia Pacific, by Route of Administration
  • Asia Pacific, by Distribution Channel

Middle East and Africa Meibomian Gland Dysfunction Treatment Market

  • Middle East and Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East and Africa
  • Middle East and Africa, by Drug Type
  • Middle East and Africa, by Route of Administration
  • Middle East and Africa, by Distribution Channel

South America Meibomian Gland Dysfunction Treatment Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Rest of South America
  • South America by Drug Type
  • South America, by Route of Administration
  • South America, by Distribution Channel

Major Companies: In this report, the major companies studied are: Pfizer, Inc., AbbVie Inc., Johnson and Johnson Service Inc., Bausch Health Companies Inc., Alcon, RegeneRx, Akorn, Inc., and Sentiss Pharma Pvt. Ltd.

Objectives of this Report:

  • To estimate the market size for the meibomian gland dysfunction treatment market on a regional and global basis
  • To identify major segments in the meibomian gland dysfunction treatment market and evaluate their market shares and demand
  • To provide a competitive scenario for the market with major developments observed by the key companies in the historic years
  • To evaluate the key factors governing the dynamics of the meibomian gland dysfunction treatment market with their potential gravity during the forecast period
  • To evaluate the leading company-wise pricing analysis for the mentioned applications

Key Questioned Answered in the Study:

  • What are major growth drivers and market trends that are impacting the global meibomian gland dysfunction treatment market?
  • What is the market size both in terms of value and volume for the global meibomian gland dysfunction treatment market?
  • Who are the leading market players and who are the new market players that operate in the global market with an estimated market share?
  • What are the future investment pockets and opportunities in the global meibomian gland dysfunction treatment market?
  • Major list of customers and potential futuristic customer list along with an estimated buying volume
  • Impact of COVID-19 on the global meibomian gland dysfunction treatment market

Customization:

This study is customized to meet your specific requirements:

  • By sub-segment
  • By client-specific country, type, and application market analysis
  • Pricing analysis along with the potential list of customers
  • Product-specific competitive analysis

For more information, contact: [email protected]

License Offering

Single User (PDF)

3850

Multi User (PDF)

5150

Enterprise User (PDF)

7650

Get Regional Report @ USD 2000 Only

Your personal details are secure. Privacy Policy

Buy Chapters of Sections

Avail customized purchase options to meet your exact research needs.

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision

Recommendations

Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements

15% Free Customization

Share your Requirements

Questions?  Speak to an Analyst

Your personal details are secure. Privacy Policy